# Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

> **NCT02896127** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 458 (actual)

## Conditions studied

- Ankylosing Spondyloarthritis

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02896127
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-18
- **Primary completion:** 2018-05-14
- **Final completion:** 2019-03-19
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2020-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896127, "Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02896127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*